Gateways to clinical trials

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 31, Issue 4, 2009, Pages 263-298

  Tomillero, A ^a   Moral, M A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACE 011; ANTIANEMIC AGENT; ANTICOAGULANT AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CARDIOVASCULAR AGENT; CENTRAL NERVOUS SYSTEM AGENTS; CONIVAPTAN; CORTICOSTEROID; DEFERASIROX; DERMATOLOGICAL AGENT; ECULIZUMAB; ELTROMBOPAG; ENOXAPARIN; FLAVOPIRIDOL; FONDAPARINUX; FUROSEMIDE; HEPARIN; IMMUNOLOGIC AGENT; IRON; NESIRITIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; PSYCHOTROPIC AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT THROMBOMODULIN; ROMIPLOSTIM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE INTERMITTENT PORPHYRIA; ACUTE LYMPHOCYTIC LEUKEMIA; AMYLOIDOSIS; ANAPLASTIC ANEMIA; ANEMIA; ATTENTION DEFICIT DISORDER; AUTOIMMUNE HEMOLYTIC ANEMIA; BONE METASTASIS; BRAIN CANCER; BREAST CANCER; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; DEPRESSION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESEARCH; DRUG SAFETY; DYSTHYMIA; ENDOCRINE TUMOR; GLIOBLASTOMA; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HEART FAILURE; HEART INFARCTION; HEMOLYTIC ANEMIA; HEPATITIS C; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPONATREMIA; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INSOMNIA; IRON OVERLOAD; KIDNEY CARCINOMA; LEUKEMIA; LOADING DRUG DOSE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; MAJOR DEPRESSION; MANIA; MANTLE CELL LYMPHOMA; MELANOMA; MESOTHELIOMA; METASTASIS; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NEUTROPENIA; NONHODGKIN LYMPHOMA; ONYCHOMYCOSIS; OVARY CANCER; PANCREAS CANCER; PERITONEUM CANCER; PROSTATE CANCER; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCHIZOPHRENIA; SKIN CARCINOMA; SOFT TISSUE CANCER; SQUAMOUS CELL CARCINOMA; ARTICLE;

CLINICAL TRIALS AS TOPIC; HUMANS;

EID: 69849091991     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2009.31.4.1373959     Document Type: Review

References (186)

1. Porter, J.B., Lin, K.-H., Habr, D., Domokos, G., Hmissi, A., Thein, S.L. Deferasirox efficacy and safety for the treatment of transfusion-dependent iron overload in patients with a range of rare anemias. Blood 2008, 112(11): Abst 1419.
2. Grant, S., Kolla, S., Sirulnik, L.A. et al. Phase I trial of vorinostat (SAHA) in combination with alvocidib (Flavopiridol) in patients with relapsed, refractory or (selected) poor prognosis acute leukemia or refractory anemia with excess blasts-2 (RAEB-2). Blood 2008, 112(11): Abst 2986.
3. Villegas, A., Arrizabalaga, B., Fernández-Lago, C. et al. Treatment of anemia with darbepoetin alfa in patients with low and intermediate-1 risk myelodysplastic syndromes: Results from the ARAMYS study. Blood 2008, 112(11): Abst 3451.
4. Suzuki, Y., Tokuda, Y., Okamoto, R. et al. Randomized, placebo-controlled phase II study of darbepoetin alfa (DA) administered every three weeks (Q3W) in patients with chemotherapy-induced anemia (CIA). Ann Oncol 2008, 19(Suppl. 8): Abst 903P.
5. Katakami, N., Nishiwaki, Y., Fujiwara, Y. et al. Randomized, double-blind, placebo-controlled phase III study of weekly administration of darbepoetin alfa (DA) in anemic patients with lung or gynecologic cancer receiving platinum-containing chemotherapy. Ann Oncol 2008, 19(Suppl. 8): Abst 904P.
6. Aikawa, N., Shimazaki, S., Yamamoto, Y. et al. Treatment effects of thrombomodulin alfa in patients with DIC associated with infection. Crit Care Med 2009, 36(12, Suppl.): Abst 56.
7. Parissis, J., Kourea, K., Andreadou, I. et al. Effects of darbepoetin-alpha on plasma markers of oxidative and nitrosative stress in anemic patients with chronic heart failure. Circulation 2008, 118(18, Suppl.): Abst 4373.
8. Weitz, I.C., Ghods, M., Rochanda, L., Liebman, H., Zwicker, J., Furie, B., Prazavi, P. Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH. Blood 2008, 112(11): Abst 407.
9. Kim, K.T., Borgstein, N.G., Yang, Y. et al. ACE-011, a soluble activin receptor type IIa IgG-Fc fusion protein, increases hemoglobin and hematocrit levels in postmenopausal healthy women. Blood 2008, 112(11): Abst 3866.
10. Min, Y.-H., Kim, H.J., Lee, K.H. et al. A multi-center, open label study evaluating the efficacy of iron chelation therapy with deferasirox in transfusional iron overload patients with myelodysplastic syndromes or aplastic anemia using quantitative R2 MRI. Blood 2008, 112(11): Abst 3649.
11. Toy, E.L., Vekeman, F., Laliberté, F. et al. Comparison of infection-related hospitalization risk and associated costs among patients receiving sargramostim (Leukine), filgrastim (Neupogen), and pegfilgrastim (Neulasta) for chemotherapy-induced neutropenia. Blood 2008, 112(11): Abst 665.
12. Cheng, G., Bussel, J.B., Saleh, M.N., Meddeb, B., De Obaldia, M.E., Aivado, M., Stone, N.L. Eltrombopag delivers clinical benefit in chronic idiopathic thrombocytopenic purpura (ITP) patients not achieving platelet counts greater than or equal to 50,000/muL-data from the EXTEND study. Blood 2008, 112(11): Abst 3430.
13. Fogarty, P.F., Bussel, J.B., Cheng, G., Saleh, M.N., Meddeb, B., Bailey, C., Brainsky, A. Oral eltrombopag treatment reduces the need for concomitant medications in patients with chronic idiopathic thrombocytopenic purpura. Blood 2008, 112(11): Abst 3424.
14. Kuter, D.J., Bussel, J.B., Newland, A. et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenic purpura (ITP): Three-year update from an open-label extension study. Blood 2008, 112(11): Abst 402.
15. Blick, S.K., Orman, J.S., Wagstaff, A.J., Scott, L.J. Spotlight on fondaparinux sodium in acute coronary syndromes. BioDrugs 2008, 22(6): 413.
16. Parker, J.D., Michaels, A.D., Malik, F.I., Wolff, A.A., Felker, G.M., Kass, D.A. Rationale and design for a phase II study evaluating the effect of the cardiac myosin activator, CK-1827452, on cardiac function, hemodynamics and myocardial oxygen consumption in patients with heart failure. J Cardiac Fail 2008, 14(6, Suppl.): Abst 254.
17. Ghali, J.K., McNutt, B., Yan, B. Conivaptan, a vasopressin-receptor antagonist, for the treatment of hyponatremia in patients with and without underlying heart failure. J Cardiac Fail 2008, 14(6, Suppl.): Abst 231.
18. Schoenland, S.O., Bochtler, T., Dietrich, S., Hegenbart, U., Goldschmidt, H., Ho, A., Klein, U. Single center experience of lenalidomide / dexamethasone treatment in 40 patients with light chain amyloidosis: High toxicity in patients with severe impaired renal and cardiac function. Blood 2008, 112(11): Abst 1736.
19. Crudu, V., Huda, N., Karia, D.H., Ra, H., Machado, R., Hoque, M.Z. Renal effects of combination infusion of high dose furosemide and nesiritide in patients with acutely decompensated heart failure. J Cardiac Fail 2008, 14(6, Suppl.): Abst 251.
20. Tepel, M.E., Hopfenmüller, W., Zidek, W., Maier, A., Scholze, A. Amlodipine prevents cardiovascular events in hypertensive hemodialysis patients. Nieren- Hochdruckkr 2008, 37(9): Abst P 009.
21. Townsend, R., Bittar, N., Rosen, J. et al. Differential blood pressure effect of naproxcinod compared with naproxen on ambulatory blood pressure in hypertensive subjects. Circulation 2008, 118(18, Suppl.): Abst 4431.
22. Taniguchi, T., Abe, M., Yagi, N. et al. Risk factors for recurrent restenosis of post-sirolimus-eluting stent restenosis: Insights from j-Cypher registry. Circ J 2008, 72(Suppl. 1): Abst OJ-218.
23. Turpie, A.G.G., Bauer, K.A., Davidson, B. et al. Once-daily oral rivaroxaban compared with subcutaneous enoxaparin every 12 hours for thromboprophylaxis after total knee replacement: RECORD4. Blood 2008, 112(11): Abst 35.
24. Turpie, A.G.G., Rud Lassen, M., Kakkar, A.K. et al. A pooled analysis of four pivotal studies of rivaroxaban for the prevention of venous thromboembolism after orthopaedic surgery: Effect on symptomatic venous thromboembolism, death, and bleeding. Blood 2008, 112(11): Abst 36.
25. Vichinsky, E., Coates, T., Thompson, A.A., Bernaudin, F., Rodriguez, M., Rojkjaer, L., Heeney, M.M. Deferasirox (Exjade), the once-daily oral iron chelator, demonstrates safety and efficacy in patients with sickle cell disease (SCD): Three and half-year follow-up. Blood 2008, 112(11): Abst 1420.
26. Budman, C., Coffey, B.J., Shechter, R., Schrock, M., Wieland, N., Spirgel, A., Simon, E. Aripiprazole in children and adolescents with Tourette disorder with and without explosive outbursts. J Child Adolesc Psychopharmacol 2008, 18(5): 509.
27. Gross, J., Gores, G., Johnson, S. Pilot study of the effects of interferon, with or without an angiotensin-2 receptor antagonist, on the expression of fibrosis-related genes in the liver of patients with chronic hepatitis C. Am J Gastroenterol 2008, 103(Suppl. 1): Abst 436.
28. Castaño, J., Garnier, C., Córcoles, D., Bulbena, A., Diaz, B., Martin, L.M., Rodriguez, L. Efficacy of duloxetine in painful symptoms with major depressive disorder. Eur Neuropsychopharmacol 2008, 18(Suppl. 4): Abst P.2.a.011.
29. Tong, W., Kantarjian, H., O'Brien, S. et al. Imatinib frontline therapy is safe and effective in patients with chronic myeloid leukemia (CML) with liver and/or renal dysfunction. Blood 2008, 112(11): Abst 2126.
30. Moreau, P., Jaccard, A., Benboubker, L. et al A multicenter phase I/II dose escalation study of lenalidomide in combination with melphalan and dexamethasone in subjects with newly-diagnosed light-chain (AL)-amyloidosis. Blood 2008, 112(11): Abst 1732.
31. Boulassel, M.-R., Yassine-Diab, B., Healey, D., Nicolette, C., Sékaly, R.-P., Routy, J.P. Impact of autologous dendritic cell immunotherapy (Arcelis) on B cell subsets in HIV-1-infected subjects receiving antiretroviral therapy. Blood 2008, 112(11): Abst 80.
32. Quirino, T., Bonfanti, P., Giuntini, R. et al. Long-term efficacy of boosted and unboosted atazanavir-containing regimens: Results from the SCOLTA project. J Int AIDS Soc 2008, 11(Suppl. 1): Abst P74.
33. Vachta, J., Wiesmann, F., Braun, P., Knechten, H., Höhn, C., Tappe, A., Ehret, R. L76V - Clinically relevant resensitization of the protease inhibitors (PIs) saquinavir (SQV) and atazanavir (ATV). J Int AIDS Soc 2008, 11(Suppl. 1): Abst P43.
34. Imaz, A., Villar Del Saz, S., Rivas, M.A. et al. Raltegravir, etravirine and darunavir-ritonavir: A safe and successful rescue regimen in highly treatment-experienced HIV-1 infected patients. J Int AIDS Soc 2008, 11(Suppl. 1): Abst P40.
35. Randell, P., Jackson, A., Nelson, M., Moyle, G. The impact of switching double-boosted protease inhibitors to darunavir/ritonavir on insulin sensitivity. Antivir Ther 2008, 13(Suppl. 4): Abst P-11.
36. Ribera, E., Antela, A., Garcia Henarejos, J.A., Ferrer, E., Oteo, J.A., Lopez Gomez, M., Arribas, J.R. Positive predictive factors in HIV-1 patients treated with enfuvirtide plus an OB that include an active boosted PI: Preliminary FastFuz study results. J Int AIDS Soc 2008, 11(Suppl. 1): Abst P44.
37. Nozza, S., Visco, F., Soria, A. et al. Excellent short-term CD4 recovery with a PI- and NRTI-sparing regimen in triple-class failure HIV-infected patients: Raltegravir, maraviroc, etravirine. J Int AIDS Soc 2008, 11(Suppl. 1): Abst P45.
38. Canestri, A., Blanc, C., Katlama, C., Peytavin, G., Ktorza, N., Wirden, M. Efficacy and safety of an antiretroviral regimen containing etravirine plus raltegravir in HIV-1 treatment-experienced patients failing darunavir. J Int AIDS Soc 2008, 11(Suppl. 1): Abst P38.
39. Da Silva, B.A., Cohen, D.E., Marsh, T.M. et al. Metabolic evaluation of study M05-730: LPV/r tablets QD vs. BID, co-administered with tenofovir DF plus emtricitabine in ARV-naïve HIV-I infected subjects. J Int AIDS Soc 2008, 11(Suppl. 1): Abst P110.
40. Almasi, F., Krivine, A., Salmon, D., Silberman, B., Belaebi, L., Compangocci, A. Efficacy and tolerance of combination of maraviroc with MK-0518, boosted TMC-114, TMC-125, in heavily pre-treated CCR5-positive patients. J Int AIDS Soc 2008, 11(Suppl. 1): Abst P46.
41. Santos, J.R., Llibre, J.M., Clotet, B., Perez, N., García, M.C., Moltó, J. Efficacy and safety of switching enfuvirtide to raltegravir in patients with viral suppression. J Int AIDS Soc 2008, 11(Suppl. 1): Abst P58.
42. Bickel, M., Bodtlaender, A., Lutz, T., Kurowski, M., Klauke, S., Knecht, G. Once-daily saquinavir (SAQ)/ritonavir (RTV) (2000/100 mg) with abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/300 mg) in naive patients. J Int AIDS Soc 2008, 11(Suppl. 1): Abst P59.
43. Eccleston, K.J., Bambumba, A., Lee, V., Ahmed, S., Babu, C.S. Efficacy and safety of tenofovir/emtricitabine compared to abacavir/lamivudine in HIV-1 infected patients in clinical setting: The TEAL study. J Int AIDS Soc 2008, 11(Suppl. 1): Abst P79.
44. Curran, A., Barragan, P., Loncà, M. et al. Long-term changes in body fat and bone mass density after switching from nucleoside reverse transcriptase inhibitors to fixed-dose tenofovir/emtricitabine or abacavir/lamivudine. Antivir Ther 2008, 13(Suppl. 4): Abst P-17.
45. Abdon, A., Cosín, J., Pasquau, J., Pedrol, E., Álvarez, M.L., Ferrer, P., Deig, E. Effectiveness and safety of HAART regimens containing tenofovir DF plus saquinavir or fosamprenavir in HIV patients: Sub-analysis from PROTECTION study. J Int AIDS Soc 2008, 11(Suppl. 1): Abst P78.
46. Esser, S., Moll, A., Cairns, V., Goldbach, J., Mauss, S., Van Lunzen, J., Jaeger, H. Safety and efficacy of tipranavir co-administered with low-dose ritonavir in patients with advanced HIV-1 infection and limited treatment options. J Int AIDS Soc 2008, 11(Suppl. 1): Abst P41.
47. Gyllensten, K., Blaxhult, A., Granholm, H. Good experience of enfuvirtide severely ill patients. J Int AIDS Soc 2008, 11(Suppl. 1): Abst P82.
48. Jones, T., Ijzerman, M., Flack, M., Arbor, A. A randomized, double-blind, vehicle-controlled trial of a novel topical antifungal nanoemulsion (NB-002) in subjects with distal subungual onychomycosis. J Am Acad Dermatol 2009, 60(3, Suppl. 1): Abst P2114.
49. Helmy, H., Rasheed, M., Al-Abd, S. Vardenafil improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: A randomized, double-blind, placebo controlled trial. Eur Urol Suppl 2009, 8(4): Abst 472.
50. Rao, M.N., Mulligan, K., Schwarz, J.-M. et al. Effects of IGF-1/IGFBP-3 treatment on glucose metabolism and fat distribution in HIV-infected patients with abdominal obesity and insulin resistance. Antivir Ther 2008, 13(Suppl. 4): Abst O-04.
51. Yoshizawa, H., Saito, M., Aogi, K. et al. Palonosetron (PALO) is more effective than granisetron (G) in preventing chemotherapy-induced nausea and vomiting (CINV) associated with cisplatin (CDDP)- or anthracycline plus cyclophosphamide (AC/EC)-based regimens: Results of a phase III trial - PALO Japanese Cooperative Study Group. Ann Oncol 2008, 19(Suppl. 8): Abst 894P.
52. Strausz, J., Rolski, J., Aziz, Z. et al. Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: 3-Day IV/oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving highly emetogenic chemotherapy (HEC). J Clin Oncol 2008, 26(15, Suppl.): Abst 20585.
53. Marre, M., Shaw, J., Brändle, M. et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009, 26(3): 268.
54. Jones, P., Fraser, N., Roth, E., Kelly, M., Gustafson, K., Setze, C., Sleep, D. ABT-335 (fenofibric acid) + rosuvastatin combination therapy in mixed dyslipidemic patients with or without type 2 diabetes mellitus. J Clin Lipidol 2008, 2(Suppl. 5): Abst 45.
55. Bays, H., Setze, C., Kelly, M., Gustafson, K., Sleep, D., Stolzenbach, J. The effect of ABT-335 (fenofibric acid) on the prevalence of metabolic syndrome in patients with mixed dyslipidemia. J Clin Lipidol 2008, 2(Suppl. 5): Abst 23.
56. Hitsumoto, T., Takahashi, M., Matsuzaki, M., Shirai, K., Iiduka, T. Comparison of atorvastatin and pitavastatin on serum lipoprotein lipase concentration in subjects with hypercholesterolemia. Circ J 2008, 72(Suppl. 1): Abst PJ-623.
57. Ziller, V., Hadji, P., Zimmermann, S. Adherence in patients with severe osteoporosis treated with teriparatide. J Bone Miner Res 2008, 23(Suppl. 1): Abst M384.
58. Dalal, M., Haiderali, A., Arondekar, B., Guckert, M. Favourable patient reported nausea and quality of life observed with casopitant, a novel neurokinin-1 (NK-1) receptor antagonist, in patients (pts) receiving highly emetogenic chemotherapy (HEC). Ann Oncol 2008, 19(Suppl. 8): Abst 890P.
59. Soria, J.C., Plummer, R., Soto, A. et al. Phase I study of the novel anti-cancer drug PM00104 as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors or lymphoma. Eur J Cancer Suppl 2008, 6(12): Abst 179.
60. Lambaki, S., Bobos, M., Kalogera-Fountzila, A. et al. EGFR status and/or ERCC1 protein expression do not predict response to concomitant radiation therapy (RT) and weekly cetuximab and cisplatin in locally advanced head and neck cancer (LA-HNC): A Hellenic Cooperative Oncology Group study. Ann Oncol 2008, 19(Suppl. 8): Abst 708P.
61. Vidal, L., Pandha, H.S., Yap, T.A. et al. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res 2008, 14(21): 7127.
62. Cesaro, S., Tridello, G., Dallorso, S., Frenos, S., Messina, C., Zanazzo, A.G. PEG-filgrastim for autologous peripheral CD34+ stem cell collection in pediatric oncological patients: A phase II study. Blood 2008, 112(11): Abst 2312.
63. Vredenburgh, J., Cloughesy, T., Prados, M. et al. A phase II, randomized, non-comparative clinical trial of bevacizumab (BV) alone or in combination with irinotecan (CPT) demonstrates prolongation of 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). Ann Oncol 2008, 19(Suppl. 8): Abst 804PD.
64. Schleyer, E., Nikolova, Z., Christian, H., Dresemann, G. Imatinib plus hydroxyurea versus hydroxyurea monotherapy in progressive glioblastoma (GBM) - An international multi-center, open label, randomised, phase III study (AMBROSIA-study). Ann Oncol 2008, 19(Suppl. 8): Abst 803PD.
65. Tolcher, A.W., Mita, M., Gordon, M. et al. Clinical responses in highly refractory solid tumor patients with oral MP-470, a multi-targeted tyrosine kinase inhibitor, in combination with standard of care chemotherapy regimens: Preliminary report from a multi-institutional phase-1b clinical trial. Eur J Cancer Suppl 2008, 6(12): Abst 403.
66. Del Conte, G., Tosi, D., Fasolo, A. et al. A phase I trial of antifibronectin 131I-L19-small immunoprotein (L19-SIP) in solid tumors and lymphoproliferative disease. J Clin Oncol 2008, 26(15, Suppl.): Abst 2575.
67. Tol, J., Koopman, M., Cats, A. et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. New Engl J Med 2009, 360(6): 563.
68. Flaig, T.W., Curti, B.D., Gordon, M.S. et al. Recombinant IL-21 in combination with sorafenib as second or third-line therapy for metastatic renal cell carcinoma (mRCC): Interim results from a phase 2 study. Eur J Cancer Suppl 2008, 6(12): Abst 204.
69. Soria, J.C., Felip, E., Herbst, R. et al. A phase I/II multicenter trial of BMS-690514 an ErbB-VEGFR inhibitor, in patients with advanced NSCLC who are erlotinib naive or previously treated with erlotinib. Eur J Cancer Suppl 2008, 6(12): Abst 392.
70. Huang, C.H., Williamson, S.K., VanVeldhuizen, P.J. et al. PDGFR inhibition using imatinib (I) combined with docetaxel (D), a potential new treatment strategy in the treatment of recurrent non-small cell lung cancer (NSCLC): Preliminary efficacy results. J Clin Oncol 2008, 26(15, Suppl.): Abst 19055.
71. Wierzbicki, R., Goss, G., Ferry, D. et al. Gefitinib (Iressa) plus best supportive care (BSC) vs placebo plus BSC in chemotherapy naive patients with advanced (stage IIIB or IV) non-small-cell lung cancer and poor performance status: Phase II randomized study. J Thorac Oncol 2008, 3(4, Suppl. 1): Abst 159O.
72. Joppert, M., Knapp, M., Jones, C.M., Boccia, R.V., Steis, R., Dakhil, S.R. A phase II trial of single-agent vinflunine as second-line treatment for advanced non-small cell lung cancer (an international oncology network study, #I-05-009). J Clin Oncol 2008, 26(15, Suppl.): Abst 19033.
73. Boulikas, T., Mylonakis, I., Rapt, J., Kosmas, A., Angel, C., Athanasiou, N. Liposomally-encapsulated cisplatin (Lipoplatin) plus gemcitabine in NSCLC: Preliminary results of a phase II trial and its antiangiogenesis potential. J Clin Oncol 2008, 26(15, Suppl.): Abst 19024.
74. Dowlati, A., Mekhail, T., O'Brien, T. et al. Phase II trial of becatecarin (rebeccamycin analogue) in relapsed sensitive small cell lung cancer (SCLC). J Clin Oncol 2008, 26(15, Suppl.): Abst 19060.
75. O'Byrne, K.J., Dunlop, D., Eberhardt, W.E., Dickgreber, N., Wagner, T.O., Capriati, A., Gillissen, A. Phase II study of sabarubicin (MEN 10755) in newly diagnosed patients with extensive stage small cell lung cancer (ESCLC): Final report. J Clin Oncol 2008, 26(15, Suppl.): Abst 19043.
76. Lunin, S.D., Spigel, D.R., Hainsworth, J.D. et al. Phase II trial of vinflunine (VFL) in sensitive and refractory relapsed small-cell lung cancer (SCLC): Updated results. J Clin Oncol 2008, 26(15, Suppl.): Abst 19028.
77. Canova, S., Cortinovis, D.L., Del Vecchio, M. et al. Italian multicenter phase II trial using fotemustine plus bevacizumab as first-line therapy in metastatic melanoma. Ann Oncol 2008, 19(Suppl. 8): Abst 788P.
78. Lawson, D.H., Gonzalez, R., Weber, R.W. et al. 2-Year overall survival (OS) results of a phase II trial of elesclomol (formerly STA-4783) and paclitaxel in stage IV metastatic melanoma (MM). J Clin Oncol 2008, 26(15, Suppl.): Abst 20023.
79. Dueland, S., Aamdal, S., Lundgren, L. et al. A multicentre, dose finding, phase II study of CP-4055 in combination with sorafenib in patients with metastatic malignant melanoma. J Clin Oncol 2008, 26(15, Suppl.): Abst 20029.
80. Hoos, A., Chasalow, S.D., Parker, S.M. et al. Ipilimumab 10 mg/kg induction dosing promotes T-cell activation in patients with advanced melanoma. Ann Oncol 2008, 19(Suppl. 8): Abst 785P.
81. González-Larriba, J.L., Guillem, V., Mármol, M., Garcia-Garcia, M., Arrivi, A., Pastor, P., Valladares, M. Open-label phase II study of sorafenib plus dacarbazine in patients with advanced metastatic melanoma. Ann Oncol 2008, 19(Suppl. 8): Abst 791P.
82. Weber, J.S., Berman, D., Hamid, O., Minor, D., Maraveyas, A., Siegel, J. Clinical activity of ipilimumab in patients with advanced melanoma and brain metastases. Ann Oncol 2008, 19(Suppl. 8): Abst 786P.
83. Mukohara, T., Nagai, S., Nambu, Y., Yoshizawa, K., Minami, H. Phase I dose escalation and pharmacokinetic study of oral enzastaurin in Japanese patients with advanced solid tumour. Eur J Cancer Suppl 2008, 6(12): Abst 421.
84. Minami, H., Mukohara, T., Nagai, S., Mukai, H., Namiki, M. A phase I study of eribulin mesylate (E7389) in patients with refractory cancers. Eur J Cancer Suppl 2008, 6(12): Abst 446.
85. Toshihiko, D., Fuse, N., Ohtsu, A. et al. Phase I dose escalation study of NK012, polymer micelle of irinotecan metabolite SN-38, in patients with advanced cancer. Eur J Cancer Suppl 2008, 6(12): Abst 423.
86. Onozawa, Y., Boku, N., Fukutomi, A. et al. A phase I dose-escalation study of TAS-102, a novel oral functional antitumor nucleoside, administered twice daily to Japanese patients (pts) with advanced solid tumors. Eur J Cancer Suppl 2008, 6(12): Abst 428.
87. Body, J., Fizazi, K., Steger, G.G. et al. Effects of denosumab on bone turnover: Results from two randomized phase 2 trials in patients with solid tumors. Ann Oncol 2008, 19(Suppl. 8): Abst 897P.
88. O'Brien, M., Clinch, Y., et al., Woll, P., Fossella, F. Phase I study of IMGN901 (BB-10901) in patients with CD56-positive solid tumours. Eur J Cancer Suppl 2008, 6(12): Abst 510.
89. Matthews, C.M., Ho, S.N., Barve, M. et al. A phase 2, single-arm study of volociximab (an anti-alpha5beta1 integrin antibody) monotherapy in patients with platinum-resistant advanced epithelial ovarian cancer or primary peritoneal cancer. Eur J Cancer Suppl 2008, 6(12): Abst 519.
90. MacVicar, G., Greco, F.A., Reeves, J. et al. An open-label, multicenter, phase 1/2 study of AT-101 in combination with docetaxel and prednisone in men with hormone refractory prostate cancer. Eur J Cancer Suppl 2008, 6(12): Abst 209.
91. Persson, B.E., Boccon-Gibod, L., Klotz, L. et al. Degarelix versus leuprolide depot (7.5 mg): Results from a 12-month, randomized, open-label, phase III study in patients with prostate cancer. Radiother Oncol 2008, 88(Suppl. 2): Abst 999.
92. Scher, H., Beer, T., Higano, C. et al. Phase I-II study of MDV3100 in castration resistant prostate cancer: The prostate cancer clinical trials consortium. Eur J Cancer Suppl 2008, 6(12): Abst 160.
93. Cohen, E.E., Davis, D.W., Karrison, T.G. et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: A phase I/II study. Lancet Oncol 2009, 10(3): 247.
94. Mohan, V., Chawla, T., Alzwahereh, K. et al. Updated results of phase II study of trabectedin (ET-743) in pretreated patients with advanced/metastatic soft tissue sarcoma from a single institute. J Clin Oncol 2008, 26(15, Suppl.): Abst 21506.
95. Pietrantuono, G., Musto, P., Villani, O. et al. Bortezomib as front-line therapy in primary plasma cell leukemia. Blood 2008, 112(11): Abst 2784.
96. Chalandon, Y., Dombret, H., Hayette, S. et al. First results of the GRAAPH-2005 study in younger adult patients with de novo Philadelphia positive acute lymphoblastic leukemia. Blood 2008, 112(11): Abst 12.
97. Lancet, J.E., Winton, E.F., Stuart, R.K. et al. A phase 1 clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias. Blood 2008, 112(11): Abst 1945.
98. Schlenk, R., Sohlbach, K., Hütter, M.-L. et al. Interim results of a phase I/II clinical trial of belinostat in combination with idarubicin in patients with AML not suitable for standard intensive therapy. Blood 2008, 112(11): Abst 1953.
99. Paolini, S., Martinelli, G., Lama, B. et al. Phase I/II study of tipifarnib and bortezomib in the treatment of poor risk adult acute leukemia. Blood 2008, 112(11): Abst 2982.
100. Faderl, S., Borthakur, G., Ravandi, F. et al. Results of a randomized phase 2 study of clofarabine plus cytarabine (CA) vs clofarabine plus idarubicin (CI) vs clofarabine, idarubicin plus cytarabine (CIA) as salvage therapy in acute myeloid leukemia (AML). Blood 2008, 112(11): Abst 964.
101. Becker, P.S., Estey, E., Petersdorf, S. et al. Phase I trial of clofarabine and high dose cytarabine with G-CSF priming (G-CLAC) for relapsed or refractory acute myeloid leukemia. Blood 2008, 112(11): Abst 2964.
102. Powell, B., D'Agostino, R., Levitan, D. et al. High dose cytarabine and clofarabine (HiDAC-CLOF) in relapsed or refractory acute myeloid leukemia, a phase 2 trial. Blood 2008, 112(11): Abst 1936.
103. Berneman, Z.N., Van De Velde, A., Van Driessche, A. et al. Immunogenicity and antileukemic activity of dendritic cells electroporated with Wilms' tumor WT1 mRNA: A phase I/II trial in acute myeloid leukemia. Blood 2008, 112(11): Abst 830.
104. Lübbert, M., Schmid, M., Rüter, B. et al. Continued treatment with an outpatient maintenance schedule of decitabine in older AML patients ineligible for induction chemotherapy: Results of the 00331 phase II multicenter trial. Blood 2008, 112(11): Abst 2965.
105. Blum, W., Klisovic, R., Liu, S. et al. Preliminary results of a phase II study of low dose decitabine as a single agent in older patients (age greater than or equal to 60) with previously untreated acute myeloid leukemia. Blood 2008, 112(11): Abst 2957.
106. O'Brien, S., Schiller, G., Giles, F., Hudak, D., Stuart, R.K. Survival after complete response to treatment with lomustine (Cloretazine) in elderly patients with de novo poor risk acute myelogenous leukemia (AML). Blood 2008, 112(11): Abst 940.
107. Uy, G.L., Rettig, M.P., McFarland, K.M. et al. Mobilization and chemosensitization of AML with the CXCR4 antagonist plerixafor (AMD3100): A phase I/II study of AMD3100+MEC in patients with relapsed or refractory disease. Blood 2008, 112(11): Abst 1944.
108. Carpenter, B., Dimopoulou, M., Manji, N. et al. T cell depletion with alemtuzumab is associated with a high incidence of EBV viraemia but low risk of PTLD following allogeneic stem cell transplantation. Blood 2008, 112(11): Abst 1177.
109. Ottmann, O.G., Spencer, A., Prince, H.M. et al. Phase IA/II study of oral panobinostat (LBH589), a novel pan-deacetylase inhibitor (DACi) demonstrating efficacy in patients with advanced hematologic malignancies. Blood 2008, 112(11): Abst 958.
110. Kirschbaum, M., Gojo, I., Goldberg, S.L. et al. Phase I study of vorinostat in combination with decitabine in patients with relapsed or newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. Blood 2008, 112(11): Abst 3651.
111. Hills, R., O'Brien, S., Giles, F., Burnett, A.K., Karsten, V. A retrospective comparison of matched elderly patients treated with laromustine (Cloretazine) or best supportive care or low dose Ara-C in the LRF AML14 trial. Blood 2008, 112(11): Abst 2960.
112. Frankfurt, O., Hamilton, E., Duffey, S. et al. Alemtuzumab and rituximab combination therapy for patients with untreated CLL - A phase II trial. Blood 2008, 112(11): Abst 2098.
113. Elter, T., James, R., Engert, A., Ritgen, M., Hallek, M., Stilgenbauer, S. Chemoimmuno-therapy with fludarabine, cyclophosphamide and alemtuzumab in patients with relapsed/refractory CLL: Interim analysis of the CLL2L trial of the German CLL study group. Blood 2008, 112(11): Abst 3170.
114. Wendtner, C.M., Knight, R.D., Stilgenbauer, S. et al. Preliminary results of a phase 1/2,multi-center,open-label study (CLL-001) investigating a stepwise dose-escalation schedule of lenalidomide in relapsed or refractory chronic-lymphocytic leukemia. Blood 2008, 112(11): Abst 2104.
115. Chen, C., Paul, H., Xu, W. et al. A phase II study of lenalidomide in previously untreated, symptomatic chronic lymphocytic leukemia (CLL). Blood 2008, 112(11): Abst 44.
116. Ferrajoli, A., O'Brien, S., Wierda, W. et al. Lenalidomide as initial treatment of elderly patients with chronic lymphocytic leukemia (CLL). Blood 2008, 112(11): Abst 45.
117. Mineishi, S., Levine, J.E., Pawarode, A. et al. Myeloablative conditioning with clofarabine and busulfan X 4 (CloBu4) is well tolerated, facilitates secure engraftment, and exhibits significant anti-tumor activity against non-remission hematologic malignancies including AML. Blood 2008, 112(11): Abst 2150.
118. Hasford, J., Lauseker, M., Gathmann, I. et al. Favorable outcome of chronic myeloid leukemia patients treated with imatinib vs early allogeneic stem cell transplantation. Blood 2008, 112(11): Abst 2123.
119. Hughes, T.P., Hochhaus, A., Branford, S. et al. Reduction of BCR-ABL transcript levels at 6, 12, and 18 months (mo) correlates with long-term outcomes on imatinib (IM) at 72 mo: An analysis from the International Randomized Study of Interferon versus STI571 (IRIS) in patients (pts) with chronic phase chronic myeloid leukemia (CML-CP). Blood 2008, 112(11): Abst 334.
120. Garg, R.J., Kantarjian, H.M., O'Brien, S., Cortes, J., Faderl, S., Estrov, Z., Quintas-Cardama, A. The use of 2nd generation tyrosine kinase inhibitors (TKI) after failure to 2 prior TKI: Long term follow-up. Blood 2008, 112(11): Abst 2119.
121. Hehlmann, R., Heimpel, H., Lauseker, M. et al. Randomized comparison of imatinib 400 mg vs. imatinib plus IFN vs. imatinib plus AraC vs. imatinib after IFN vs. imatinib 800 mg: Optimized treatment and survival: Designed first interim analysis of the German CML study IV. Blood 2008, 112(11): Abst 184.
122. Cortes, J., Baccarani, M., Guilhot, F. et al. A phase III, randomized, open-label study of 400 mg versus 800 mg of imatinib mesylate (IM) in patients (pts) with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP) using molecular endpoints: One-year results of TOPS (Tyrosine Kinase Inhibition, Optimization and Selectivity) study. Blood 2008, 112(11): Abst 335.
123. Petzer, A.L., Gastl, G., Fong, D. et al. CELSG CML 11 "ISTAHIT" phase III study - planned interim analysis: High doses of imatinib mesylate (800mg/day) significantly improve rates of major and complete cytogenetic remissions (MCR, CCR) in pretreated ph+/BCR-ABL+ CML patients in chronic phase. Blood 2008, 112(11): Abst 1112.
124. Czuczman, M.S., Vose, J.M., Zinzani, P.L. et al. Confirmation of the efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory diffuse large-B-cell lymphoma: Results of an international study (NHL-003). Blood 2008, 112(11): Abst 268.
125. Vitolo, U., Morschhauser, F., Radford, J.A. et al. Consolidation of first remission with 90Y-ibritumomab tiuxetan in advanced follicular non-Hodgkin's lymphoma (FL): Results from the phase 3 randomized First-line Indolent Trial (FIT). Ann Oncol 2008, 19(Suppl. 8): Abst 738P.
126. Fehniger, T.A., Larson, S., Trinkaus, K. et al. A phase II multicenter study of lenalidomide in patients with relapsed or refractory classical Hodgkin's lymphoma (cHL): Preliminary results. Blood 2008, 112(11): Abst 2595.
127. Wang, M., Zhang, L., Fayad, L. et al. Lenalidomide and rituximab are a promising combination in vitro, in vivo preclinically and in a phase I/II clinical trial in relapsed/refractory mantle cell lymphoma. Blood 2008, 112(11): Abst 3058.
128. DeRook, I., Odonnell, R.T., Tuscano, J., Quirch, C., Noble, B. R2: Preliminary results of a phase II study of lenalidomide and rituximab in relapsed/refractory indolent non-Hodgkin's lymphoma (NHL). Blood 2008, 112(11): Abst 3060.
129. Lin, T.S., Heerema, N.A., Lozanski, G. et al. Flavopiridol (Alvocidib) induces durable responses in relapsed chronic lymphocytic leukemia (CLL) patients with high-risk cytogenetic abnormalities. Blood 2008, 112(11): Abst 46.
130. Vanazzi, A., Ferrucci, P.F., Grana, C.M. et al. Efficacy of 90Y-ibritumomab tiuxetan in relapsed or refractory primary gastric non-Hodgkin's lymphoma. Blood 2008, 112(11): Abst 3063.
131. Evens, A.M., Gordon, L.I., Patton, D. et al. Phase I results of combination gemcitabine and bortezomib (VELCADE) for relapsed/refractory nodal T-cell non-Hodgkin lymphoma (T-NHL) and aggressive B-cell NHL (B-NHL). Blood 2008, 112(11): Abst 2005.
132. Mateos, M.-V., Cibeira, M.T., Richardson, P. et al. Final results of a phase II trial with plitidepsin (Aplidin) alone and in combination with dexamethasone in patients with relapsed/refractory multiple myeloma. Blood 2008, 112(11): Abst 3700.
133. Hozo, I., Kumar, A., Djulbegovic, B. Thalidomide versus bortezomib-based regimens for relapsed myeloma: Meta-analysis and indirect meta-analysis. Blood 2008, 112(11): Abst 2362.
134. Richardson, P., Anderson, K.C., Jakubowiak, A. et al. Lenalidomide, bortezomib, and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (MM): Encouraging response rates and tolerability with correlation of outcome and adverse cytogenetics in a phase II study. Blood 2008, 112(11): Abst 1742.
135. Hrusovsky, I., Emmerich, B., Von Rohr, A. et al. Bortezomib retreatment
136. Knop, S., Einsele, H., Wandt, H. et al. Bortezomib, intravenous cyclophosphamide and dexamethasone (VelCD) for previously untreated multiple myeloma: An interim analysis of the German DSMM XIa trial. Blood 2008, 112(11): Abst 2776.
137. Gasparetto, C., Rizzieri, D.A., Diehl, L.F. et al. Bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for non-transplant candidates in patients with previously untreated multiple myeloma. Blood 2008, 112(11): Abst 3325.
138. Eom, H.S., Kim, Y.-K., Chung, J.-S. et al. Velcade, thalidomide, dexamethasone (VTD) followed by melphalan, prednisone, thalidomide (MPT) maintenance as a first line treatment demonstrates high response rates for high-risk patients with multiple myeloma (MM) who are non-transplant candidates: Updated results of phase II trial. Blood 2008, 112(11): Abst 2785.
139. San Miguel, J.F., Richardson, P., Khuageva, N.K. et al. Updated follow-up and results of subsequent therapy in the phase III VISTA trial: Bortezomib plus melphalan-prednisone versus melphalan-prednisone in newly diagnosed multiple myeloma. Blood 2008, 112(11): Abst 650.
140. Bahlis, N.J., Song, K.W., Fu, T. et al. The impact of cytogenetics on the outcomes of treatment with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Blood 2008, 112(11): Abst 1731.
141. DiPersio, J.F., Stadtmauer, E.A., Nademanee, A.P., Calandra, G., Stiff, P.J., Bridger, G., Micallef, I.N.M. 12 Months report from a phase 3 study of plerixafor plus G-CSF vs. placebo plus G-CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with multiple myeloma. Blood 2008, 112(11): Abst 3312.
142. Chanan-Khan, A.A., Gharibo, M., Jagannath, S. ET AL. Phase I study of IMGN901 in patients with relapsed and relapsed/refractory CD56-positive multiple myeloma. Blood 2008, 112(11): Abst 3689.
143. Quach, H., Ritchie, D., Neeson, P. et al. Regulatory T cells (Treg) are depressed in patients with relapsed/refractory multiple myeloma (MM) and increases towards normal range in responding patients treated with lenalidomide (LEN). Blood 2008, 112(11): Abst 1696.
144. Gerecke, C., Knop, S., Topp, M.S. et al. Lenalidomide, adriamycin and dexamethasone (RAD) in relapsed and refractory multiple myeloma: Final results from a phase I/II trial of "Deutsche Studiengruppe Multiples Myelom". Blood 2008, 112(11): Abst 2782.
145. Siegel, D., Sezer, O., San Miguel, J.F. et al. A phase Ib, multicenter, openlabel, dose-escalation study of oral panobinostat (LBH589) and I.V. bortezomib in patients with relapsed multiple myeloma. Blood 2008, 112(11): Abst 2781.
146. Richardson, P., Hofmeister, C.C., Zimmerman, T.M. et al. Phase 1 clinical trial of NPI-0052, a novel proteasome inhibitor in patients with multiple myeloma. Blood 2008, 112(11): Abst 2770.
147. Wierda, W.G., Chen, R., Plunkett, W. et al. A phase 1 trial of SNS-032, a potent and specific CDK 2, 7 and 9 inhibitor, in chronic lymphocytic leukemia and multiple myeloma. Blood 2008, 112(11): Abst 3178.
148. Greiner, J., Schmitt, A., Giannopoulos, K. et al. High-dose RHAMM-R3 peptide vaccination for patients with vaccination for patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), multiple myeloma (MM) and lymphocytic leukemia (CLL). Blood 2008, 112(11): Abst 2911.
149. Duvic, M., Becker, J.C., Dalle, S. et al. Phase II trial of oral panobinostat (LBH589) in patients with refractory cutaneous T-cell lymphoma (CTCL). Blood 2008, 112(11): Abst 1005.
150. Kumar, A., Djulbegovic, B., Mhaskar, R., List, A.F. Efficacy of hypo-methylating agents in the treatment of myelodysplastic syndromes: A systematic review and meta-analysis of randomized controlled trials. Blood 2008, 112(11): Abst 3632.
151. Seymour, J.F., Fenaux, P., Silverman, L.B. et al. Effects of azacitidine (AZA) vs. conventional care regimens (CCR) in elderly (greater than or equal to 75 years) patients (pts) with myelodysplastic syndromes (MDS) from the AZA-001survival trial. Blood 2008, 112(11): Abst 3629.
152. Fenaux, P., Mufti, G.J., Hellstrom-Lindberg, E. et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study. Lancet Oncol 2009, 10 (3): 223.
153. Santini, V., Fenaux, P., Mufti, G.J. et al. Management and supportive care measures of adverse events (AEs) in higher-risk MDS patients (pts) treated with azacitidine (AZA). Blood 2008, 112(11): Abst 1653.
154. Rachmilewitz, E., Merkel, D., Ghoti, H. et al. Improvement of oxidative stress parameters in MDS patients with iron overload treated with deferasirox. Blood 2008, 112(11): Abst 2675.
155. Howard, D., Liesveld, J., Jordan, C.T. et al. A phase I study using bortezomib with weekly idarubicin for the treatment of elderly (greater than 60 years) and relapsed patients with acute myeloid leukemia (AML). Blood 2008, 112(11): Abst 2953.
156. Burnett, A.K., Hills, R., Milligan, D. et al. Low dose Ara-C versus low dose Ara-C and tipifarnib: Result of the UK NCRI AML16 "Pick A Winner" comparison. Blood 2008, 112(11): Abst 2962.
157. List, A.F., Baer, M.R., Steensma, D. et al. Iron chelation with deferasirox (Exjade) improves iron burden in patients with myelodysplastic syndromes (MDS). Blood 2008, 112(11): Abst 634.
158. Jabbour, E., Garcia-Manero, G., Shan, J. et al. Outcome of patients (pts) with myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) post decitabine failure. Blood 2008, 112(11): Abst 1659.
159. Mesa, R.A., Yao, X., Tallman, M.S. et al. Lenalidomide and prednisone for primary and post polycythemia vera/essential thrombocythemia myelofibrosis (MF): An Eastern Cooperative Oncology Group (ECOG) phase II trial. Blood 2008, 112(11): Abst 1753.
160. Nofzinger, E., Buysse, D.J., Price, J. et al. Eszopiclone reverses brain hyperarousal in insomnia patients: Evidence from [18F]-FDG PET. Eur Neuropsychopharmacol 2008, 18(Suppl. 4): Abst P.1.e.008.
161. Adler, L.A., Goodman, D.W., Kollins, S.H. et al. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2008, 69(9): 1364.
162. Kennedy, S.H. Efficacy of agomelatine from treatment initiation to treatment completion. Eur Neuropsychopharmacol 2008, 18(Suppl. 4): Abst P.2.a.001.
163. Istikoglou, C., Mavreas, V., Vlissides, D. Comparative study on the effectiveness of anti-depressing treatment between St John's Wort and duloxetine. Eur Neuropsychopharmacol 2008, 18(Suppl. 4): Abst P.2.a.008.
164. Kornstein, S.G., Dunner, D.L., Meyers, A.L. et al. A randomized, double-blind study of increasing or maintaining duloxetine dose in patients without remission of major depressive disorder after initial duloxetine therapy. J Clin Psychiatry 2008, 69(9): 1383.
165. Kasper, S., Boulenger, J.P., Baldwin, D. Pooled analysis: 2 Randomised clinical trials confirms superiority of escitalopram over paroxetine in treatment of major depressive disorder. Eur Neuropsychopharmacol 2008, 18(Suppl. 4): Abst P.2.a.009.
166. Konarski, J.Z., Kennedy, S.H., Wunderlich, G., Pyke, R. Effects of acute flibanserin on FDG-PET brain glucose metabolism in men with major depressive disorder. Eur Neuropsychopharmacol 2008, 18(Suppl. 4): Abst P.1.c.044.
167. Vasiliu, D., Vasiliu, O., Ojog, D., Patriche, D., Stanescu, B., Tudor, C. Venlafaxine versus selective serotonin reuptake inhibitors in mixed major depression and dysthymic disorder. Eur Neuropsychopharmacol 2008, 18(Suppl. 4): Abst P.2.a.033.
168. Peuskens, J., Halkin, V., Kerselaers, W., De Patoul, A. Evaluation of the effectiveness and effect on cognitive functioning of aripiprazole in a range of schizophrenia patients. Eur Neuropsychopharmacol 2008, 18(Suppl. 4): Abst P.3.c.077.
169. Donoghue, J.M. An evaluation of the clinical value of aripiprazole in the treatment of mania. Eur Neuropsychopharmacol 2008, 18(Suppl. 4): Abst P.3.c.057.
170. Fleischhacker, W., Heikkinen, M.E., Olie, J.P. et al. Long-term effect on weight of aripiprazole-clozapine in schizophrenia patients with suboptimal response on clozapine. Eur Neuropsychopharmacol 2008, 18(Suppl. 4): Abst P.3.c.076.
171. Schreiner, A., Ibach, B. Interim-analysis of a long-term treatment study with long-acting injectable risperidone and oral second generation antipsychotics in schizophrenia. Eur Neuropsychopharmacol 2008, 18(Suppl. 4): Abst P.3.c.058.
172. Nuernberger, J., Witzke, O., Rother, R.P et al. Successful treatment of atypical hemolytic uremic syndrome with the complement inhibitor eculizumab. Blood 2008, 112(11): Abst 2294.
173. Wiesholzer, M. Reduced dose requirement after switching from rHuEPO to darbepoetin-alpha in patients undergoing hemodialysis. Nieren-Hochdruckkr 2008, 37(9): Abst P 004.
174. Dahl, O.E., Kurth, A.A., Rosencher, N., Eriksson, B.I., Clemens, A., Noack, H., Schnee, J. Efficacy and safety profile of dabigatran etexilate for the prevention of venous thromboembolism in moderately renally impaired patients after total knee or hip replacement surgery. Blood 2008, 112(11): Abst 981.
175. Maass, E., Bramlage, C.P., Koziolek, M., Müller, G.A., Homayounfar, K. Improvement of renal allograft function after conversion from calcineurin inhibitors to enteric coated mycophenolic acid. Nieren- Hochdruckkr 2008, 37(9): Abst P 299.
176. Seitz, C., Schürmann, R., Marr, J., Gerlinger, C. A double-blind placebo-controlled trial investigating the efficacy of 12 weeks of dienogest 2 mg/day for the treatment of endometriosis-associated pain. Fertil Steril 2008, 90(Suppl. 1): Abst P-90.
177. Kaygusuz, I., Turhan, N.Ö:, Koca, C., Duvan, C.I., Isik, B., Kafali, H. Effect of genistein therapy on plasma levels of asymmetric dimethylarginine in healthy postmenopausal women: A randomized, placebo-controlled study. Fertil Steril 2008, 90(Suppl. 1): Abst O-153.
178. Corren, J., Busse, W., Meltzer, E. et al. Efficacy and safety of AMG 317, an IL-4Ra antagonist, in atopic asthmatic subjects: A randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol 2009, 123(2, Suppl.): Abst LB33.
179. Gomes, J.P., Georgy, A., Wolff, G., Farid, A., Bantia, S., Passe, S. A phase II study of the purine nucleoside phosphorylase (PNP) inhibitor RO5092888 (BCX-4208) in patients with moderate to severe chronic plaque psoriasis: Safety, tolerability and lymphocyte effects. Blood 2008, 112(11): Abst 2583.
180. Frey, S.E., Newman, F.K., Kennedy, J.S. et al. Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax® in healthy vaccinia-naive adults. Vaccine 2009, 27 (10):1637.
181. Samama, M.M., Kunitada, S., Haque, N., Depasse, F., Oursin, A. Study of coagulation and platelets response in an open label randomised non treatment and active controlled (dalteparin, ximelagatran and DU-176b) in 4 groups of elderly healthy subjects. Blood 2008, 112(11): Abst 3026.
182. Trellu, M., Paquet, N., Paty, I., Perez, Y., Ortiz, J., Sibille, M. The efficacy and safety of re-administering avidin to reverse the anticoagulant activity of biotinylated idraparinux in healthy subjects. Eur Heart J 2008, 29(Suppl.): Abst P2073.
183. Randell, P., Jackson, A., Dennis, K., Moyle, G. The impact of raltegravir and lopinavir/ritonavir on peripheral glucose disposal in HIV-negative subjects. Antivir Ther 2008, 13(Suppl. 4): Abst O-25.
184. Jordan, R., Stark, J., Fischkoff, S.A., Lata, J., Hallam, T., Huskey, S. Phase I study of the novel A-type natriuretic receptor agonist, PL-3994, in healthy volunteers. J Cardiac Fail 2008, 14(6, Suppl.): Abst 220.
185. Hjelmström, P., Gyaw, S., Lindenstroem, E., Hallén, B. Sym001, the first recombinant polyclonal rhesus-D specific antibody product, was safe and well-tolerated in a placebo-controlled randomized phase I trial. Blood 2008, 112(11): Abst 1987.
186. Blum, R., Adams, L.M., Johnson, B.M., Lebowitz, P.F., Eberwein, D.J., Allred, A.J., Zhang, K. Effect of casopitant, a novel neurokinin -1 (NK-1) receptor antagonist for prevention of chemotherapy induced nausea and vomiting (CINV), on the pharmacokinetics (PK) and pharmacodynamics (PD) of steady-state warfarin. J Clin Oncol 2008, 26(15, Suppl.): Abst 20587.